Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment

Comments Follow Plans For Novartis To Spin Sandoz

Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.

Timeline years 2025 blue pin
Sandoz has outlined launches up to 2025 and beyond • Source: Olivier Le Moal / Alamy Stock Photo

More from Biosimilars

More from Products